Novartis is eyeing approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma More: Priority review for Novartis CAR-T cell therapy Kymriah Source: News
read moreThe development of the device is being carried out by Aptar Pharma’s Digital Health group More: Stallergenes Greer and Aptar Pharma to develop immunotherapy treatment device Source: News
read moreOpposition leaders have emphasised that more than 100,000 people eligible for a third dose have not yet received it More: Sturgeon urged to speed COVID booster jab rollout as vulnerable groups left waiting Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals